Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF)

Ticagrelor is one of the most powerful P2Y(12) inhibitor. We have recently reported that, in patients with concomitant Stable Coronary Artery Disease (SCAD) and Chronic Obstructive Pulmonary Disease (COPD) undergoing percutaneous coronary intervention (PCI), treatment with ticagrelor, as compared to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Physiol
Main Authors: Vieceli Dalla Sega, Francesco, Fortini, Francesca, Aquila, Giorgio, Pavasini, Rita, Biscaglia, Simone, Bernucci, Davide, Del Franco, Annamaria, Tonet, Elisabetta, Rizzo, Paola, Ferrari, Roberto, Campo, Gianluca
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Physiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5900783/
https://ncbi.nlm.nih.gov/pubmed/29686623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2018.00337
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados